The giant Chinese pharmaceutical’s preventive vaccine is entering a new phase, bringing it closer to future commercialization.
Image credit: EqualOcean
Fosun Pharma’s COVID-19 preventive vaccine has been approved by the National Medical Products Administration to enter clinical trials. If the vaccine passes Phase III, it can officially go to the market into a commercial-stage. Considering the large-scale impact brought by the pandemic, there is a considerable consumption market for prevention.
The progress is the fruit of cooperative work. Exclusively authorized this March by BioNTech SE (BNTX:Nasdaq), Germany-based biotechnology, Fosun Pharma has been developing an mRNA-based vaccine for COVID-19 and owns the related commercial rights.
Computing power is productivity: An infrastructure competition concerning the next ten years
May 20, 2026 11:05 AM
From a "Huawei substitute" to falling out of the top five: Where exactly did Honor lose?
May 19, 2026 12:00 PM